Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study
We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologicall...
Gespeichert in:
Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2014-12, Vol.31 (12), p.369-369, Article 369 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 369 |
---|---|
container_issue | 12 |
container_start_page | 369 |
container_title | Medical oncology (Northwood, London, England) |
container_volume | 31 |
creator | Li, Chongyi Xiong, Yanli Zhou, Zejun Peng, Yu Huang, Huan Xu, Mingfang Kang, Houyi Peng, Bo Wang, Dong Yang, Xueqin |
description | We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologically proven LS-SCLC received 4–6 cycles of cisplatin 75 mg/(m
2
/day) given intravenously on day 1 and etoposide 80 mg/(m
2
/day) given intravenously on days 1–5, both at 3 weekly intervals. SBRT at a dose of 4,000–4,500 cGy in ten fractions was given concurrently with chemotherapy starting on day 1. The Kaplan–Meier curve and life tables were used to describe survival data. Adverse events were evaluated according to the common terminology criteria for adverse events version of the radiation therapy oncology group (RTOG). Twenty-nine patients were included and followed up for a median duration of 19 (range 10–85) months. The median OS was 27 (95 % CI 20.2–33.8) months. The median PFS was 12 (95 % CI 4.2–19.8) months. No grade 4 adverse events were observed. Grade 3 adverse events occurred in only 5 (13.8 %, 5/29) patients. Neutropenia of any grade was observed in 6 (15 %, 6/29) patients, with grade 3 neutropenia only seen in one (3.4 %, 1/29) patient. The combination of chemotherapy and early concurrent SBRT could be a safe and effective treatment for LS-SCLC patients. Our study confirmed that SBRT with concurrent chemotherapy is another new treatment option for LS-SCLC patients. |
doi_str_mv | 10.1007/s12032-014-0369-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1627961458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3508798671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-6123dcfc41684e92ca5c382bcdac34f08f71d1fcbe53d47b6756474bc1371133</originalsourceid><addsrcrecordid>eNp1kctuFDEQRVuIiITAB7BBltiwaeLyox_sUMRjpEhZkAW7lrtcPeOoX9juYean-EY86hAhpGxsS3Xu9S3dLHsD_ANwXl4FEFyKnIPKuSzq_PAsuwCt6xwk_Hie3lKXOdcFP89ehnDPuQAt6hfZudAKCq7FRfb7eyRPUzQYHbJ2skfmjXVT3JE385H9cnHHcBpx8Z7GyHBHw-OQDpFGG1hY_N7tTc-mjs0mugSGVdm7wUWyLESzJRYG0_cMKR39Mm4ZmhHJf2SGBTdue8oxKcmz2U9hppRoT2zemUBss0kWiz2-ys460wd6_XBfZndfPt9df8tvbr9urj_d5KiUiHkBQlrsMG1ZKaoFGo2yEi1ag1J1vOpKsNBhS1paVbZFqQtVqhZBlgBSXmbvV9uU5OdCITaDC6fcZqRpCQ0UoqwLULpK6Lv_0Ptp8WMKd6IqKAvO60TBSmFaLXjqmtm7wfhjA7w5ddmsXTapy-bUZXNImrcPzks7kH1U_C0vAWIFQhqNW_L_fP2k6x8yzK6E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1628176009</pqid></control><display><type>article</type><title>Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Li, Chongyi ; Xiong, Yanli ; Zhou, Zejun ; Peng, Yu ; Huang, Huan ; Xu, Mingfang ; Kang, Houyi ; Peng, Bo ; Wang, Dong ; Yang, Xueqin</creator><creatorcontrib>Li, Chongyi ; Xiong, Yanli ; Zhou, Zejun ; Peng, Yu ; Huang, Huan ; Xu, Mingfang ; Kang, Houyi ; Peng, Bo ; Wang, Dong ; Yang, Xueqin</creatorcontrib><description>We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologically proven LS-SCLC received 4–6 cycles of cisplatin 75 mg/(m
2
/day) given intravenously on day 1 and etoposide 80 mg/(m
2
/day) given intravenously on days 1–5, both at 3 weekly intervals. SBRT at a dose of 4,000–4,500 cGy in ten fractions was given concurrently with chemotherapy starting on day 1. The Kaplan–Meier curve and life tables were used to describe survival data. Adverse events were evaluated according to the common terminology criteria for adverse events version of the radiation therapy oncology group (RTOG). Twenty-nine patients were included and followed up for a median duration of 19 (range 10–85) months. The median OS was 27 (95 % CI 20.2–33.8) months. The median PFS was 12 (95 % CI 4.2–19.8) months. No grade 4 adverse events were observed. Grade 3 adverse events occurred in only 5 (13.8 %, 5/29) patients. Neutropenia of any grade was observed in 6 (15 %, 6/29) patients, with grade 3 neutropenia only seen in one (3.4 %, 1/29) patient. The combination of chemotherapy and early concurrent SBRT could be a safe and effective treatment for LS-SCLC patients. Our study confirmed that SBRT with concurrent chemotherapy is another new treatment option for LS-SCLC patients.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-014-0369-x</identifier><identifier>PMID: 25416052</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemoradiotherapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Disease-Free Survival ; Etoposide - administration & dosage ; Etoposide - adverse effects ; Female ; Hematology ; Humans ; Internal Medicine ; Kaplan-Meier Estimate ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - surgery ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neutropenia - chemically induced ; Oncology ; Original Paper ; Pathology ; Prospective Studies ; Radiosurgery - methods ; Small Cell Lung Carcinoma - drug therapy ; Small Cell Lung Carcinoma - mortality ; Small Cell Lung Carcinoma - surgery ; Treatment Outcome</subject><ispartof>Medical oncology (Northwood, London, England), 2014-12, Vol.31 (12), p.369-369, Article 369</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-6123dcfc41684e92ca5c382bcdac34f08f71d1fcbe53d47b6756474bc1371133</citedby><cites>FETCH-LOGICAL-c442t-6123dcfc41684e92ca5c382bcdac34f08f71d1fcbe53d47b6756474bc1371133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-014-0369-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-014-0369-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25416052$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Chongyi</creatorcontrib><creatorcontrib>Xiong, Yanli</creatorcontrib><creatorcontrib>Zhou, Zejun</creatorcontrib><creatorcontrib>Peng, Yu</creatorcontrib><creatorcontrib>Huang, Huan</creatorcontrib><creatorcontrib>Xu, Mingfang</creatorcontrib><creatorcontrib>Kang, Houyi</creatorcontrib><creatorcontrib>Peng, Bo</creatorcontrib><creatorcontrib>Wang, Dong</creatorcontrib><creatorcontrib>Yang, Xueqin</creatorcontrib><title>Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologically proven LS-SCLC received 4–6 cycles of cisplatin 75 mg/(m
2
/day) given intravenously on day 1 and etoposide 80 mg/(m
2
/day) given intravenously on days 1–5, both at 3 weekly intervals. SBRT at a dose of 4,000–4,500 cGy in ten fractions was given concurrently with chemotherapy starting on day 1. The Kaplan–Meier curve and life tables were used to describe survival data. Adverse events were evaluated according to the common terminology criteria for adverse events version of the radiation therapy oncology group (RTOG). Twenty-nine patients were included and followed up for a median duration of 19 (range 10–85) months. The median OS was 27 (95 % CI 20.2–33.8) months. The median PFS was 12 (95 % CI 4.2–19.8) months. No grade 4 adverse events were observed. Grade 3 adverse events occurred in only 5 (13.8 %, 5/29) patients. Neutropenia of any grade was observed in 6 (15 %, 6/29) patients, with grade 3 neutropenia only seen in one (3.4 %, 1/29) patient. The combination of chemotherapy and early concurrent SBRT could be a safe and effective treatment for LS-SCLC patients. Our study confirmed that SBRT with concurrent chemotherapy is another new treatment option for LS-SCLC patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemoradiotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Disease-Free Survival</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - adverse effects</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neutropenia - chemically induced</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Prospective Studies</subject><subject>Radiosurgery - methods</subject><subject>Small Cell Lung Carcinoma - drug therapy</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Small Cell Lung Carcinoma - surgery</subject><subject>Treatment Outcome</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kctuFDEQRVuIiITAB7BBltiwaeLyox_sUMRjpEhZkAW7lrtcPeOoX9juYean-EY86hAhpGxsS3Xu9S3dLHsD_ANwXl4FEFyKnIPKuSzq_PAsuwCt6xwk_Hie3lKXOdcFP89ehnDPuQAt6hfZudAKCq7FRfb7eyRPUzQYHbJ2skfmjXVT3JE385H9cnHHcBpx8Z7GyHBHw-OQDpFGG1hY_N7tTc-mjs0mugSGVdm7wUWyLESzJRYG0_cMKR39Mm4ZmhHJf2SGBTdue8oxKcmz2U9hppRoT2zemUBss0kWiz2-ys460wd6_XBfZndfPt9df8tvbr9urj_d5KiUiHkBQlrsMG1ZKaoFGo2yEi1ag1J1vOpKsNBhS1paVbZFqQtVqhZBlgBSXmbvV9uU5OdCITaDC6fcZqRpCQ0UoqwLULpK6Lv_0Ptp8WMKd6IqKAvO60TBSmFaLXjqmtm7wfhjA7w5ddmsXTapy-bUZXNImrcPzks7kH1U_C0vAWIFQhqNW_L_fP2k6x8yzK6E</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Li, Chongyi</creator><creator>Xiong, Yanli</creator><creator>Zhou, Zejun</creator><creator>Peng, Yu</creator><creator>Huang, Huan</creator><creator>Xu, Mingfang</creator><creator>Kang, Houyi</creator><creator>Peng, Bo</creator><creator>Wang, Dong</creator><creator>Yang, Xueqin</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20141201</creationdate><title>Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study</title><author>Li, Chongyi ; Xiong, Yanli ; Zhou, Zejun ; Peng, Yu ; Huang, Huan ; Xu, Mingfang ; Kang, Houyi ; Peng, Bo ; Wang, Dong ; Yang, Xueqin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-6123dcfc41684e92ca5c382bcdac34f08f71d1fcbe53d47b6756474bc1371133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemoradiotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Disease-Free Survival</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - adverse effects</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neutropenia - chemically induced</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Prospective Studies</topic><topic>Radiosurgery - methods</topic><topic>Small Cell Lung Carcinoma - drug therapy</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Small Cell Lung Carcinoma - surgery</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Chongyi</creatorcontrib><creatorcontrib>Xiong, Yanli</creatorcontrib><creatorcontrib>Zhou, Zejun</creatorcontrib><creatorcontrib>Peng, Yu</creatorcontrib><creatorcontrib>Huang, Huan</creatorcontrib><creatorcontrib>Xu, Mingfang</creatorcontrib><creatorcontrib>Kang, Houyi</creatorcontrib><creatorcontrib>Peng, Bo</creatorcontrib><creatorcontrib>Wang, Dong</creatorcontrib><creatorcontrib>Yang, Xueqin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Chongyi</au><au>Xiong, Yanli</au><au>Zhou, Zejun</au><au>Peng, Yu</au><au>Huang, Huan</au><au>Xu, Mingfang</au><au>Kang, Houyi</au><au>Peng, Bo</au><au>Wang, Dong</au><au>Yang, Xueqin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>31</volume><issue>12</issue><spage>369</spage><epage>369</epage><pages>369-369</pages><artnum>369</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologically proven LS-SCLC received 4–6 cycles of cisplatin 75 mg/(m
2
/day) given intravenously on day 1 and etoposide 80 mg/(m
2
/day) given intravenously on days 1–5, both at 3 weekly intervals. SBRT at a dose of 4,000–4,500 cGy in ten fractions was given concurrently with chemotherapy starting on day 1. The Kaplan–Meier curve and life tables were used to describe survival data. Adverse events were evaluated according to the common terminology criteria for adverse events version of the radiation therapy oncology group (RTOG). Twenty-nine patients were included and followed up for a median duration of 19 (range 10–85) months. The median OS was 27 (95 % CI 20.2–33.8) months. The median PFS was 12 (95 % CI 4.2–19.8) months. No grade 4 adverse events were observed. Grade 3 adverse events occurred in only 5 (13.8 %, 5/29) patients. Neutropenia of any grade was observed in 6 (15 %, 6/29) patients, with grade 3 neutropenia only seen in one (3.4 %, 1/29) patient. The combination of chemotherapy and early concurrent SBRT could be a safe and effective treatment for LS-SCLC patients. Our study confirmed that SBRT with concurrent chemotherapy is another new treatment option for LS-SCLC patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25416052</pmid><doi>10.1007/s12032-014-0369-x</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1357-0560 |
ispartof | Medical oncology (Northwood, London, England), 2014-12, Vol.31 (12), p.369-369, Article 369 |
issn | 1357-0560 1559-131X |
language | eng |
recordid | cdi_proquest_miscellaneous_1627961458 |
source | MEDLINE; SpringerNature Journals |
subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemoradiotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Disease-Free Survival Etoposide - administration & dosage Etoposide - adverse effects Female Hematology Humans Internal Medicine Kaplan-Meier Estimate Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - surgery Male Medicine Medicine & Public Health Middle Aged Neutropenia - chemically induced Oncology Original Paper Pathology Prospective Studies Radiosurgery - methods Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - surgery Treatment Outcome |
title | Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A28%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20body%20radiotherapy%20with%20concurrent%20chemotherapy%20extends%20survival%20of%20patients%20with%20limited%20stage%20small%20cell%20lung%20cancer:%20a%20single-center%20prospective%20phase%20II%20study&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Li,%20Chongyi&rft.date=2014-12-01&rft.volume=31&rft.issue=12&rft.spage=369&rft.epage=369&rft.pages=369-369&rft.artnum=369&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-014-0369-x&rft_dat=%3Cproquest_cross%3E3508798671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1628176009&rft_id=info:pmid/25416052&rfr_iscdi=true |